胰岛素联合西格列汀治疗成人隐匿性自身免疫糖尿病早期患者的疗效观察

doi:10.3969/j.issn.1000-8535.2017.04.011

广州医药 ›› 2017, Vol. 48 ›› Issue (4): 46-50.DOI: 10.3969/j.issn.1000-8535.2017.04.011

胰岛素联合西格列汀治疗成人隐匿性自身免疫糖尿病早期患者的疗效观察

赖菲菲¹, 李枢¹, 王吓勇²

1 广东省惠州市中心人民医院内分泌科(惠州 516001)
2 惠州市口腔医院(惠州 516001)

收稿日期:2017-03-14 发布日期:2021-12-01

Insulin with dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults

LAI Feifei¹, LI Shu¹, WANG Xiayong²

1 Department of Endocrinology, Guangdong Huizhou Center People's Hospital, Huizhou 516001,China
2 Hospital of Stomatology Huizhou,Huizhou 516001,China

Received:2017-03-14 Published:2021-12-01

摘要/Abstract

摘要： 目的探讨DPP-4抑制剂西格列汀对成人隐匿性自身免疫性糖尿病(LADA)早期患者胰岛β细胞功能的影响。方法把14例新诊断为LADA患者随机分为两组,胰岛素治疗100 mg/d西格列汀(A组,n=7)或无西格列汀(B组,n=7)共治疗9个月。结果 9个月后两组之间的血糖和糖化血红蛋白水平无差异。9个月后A组空腹C肽(FCP),餐后C肽(CP),和ΔCP(ΔCP=2 h CP-FCP)水平与基线相比无明显差别(P＞0.05),B组FCP,2 h的CP和ΔCP进行比较基线显著下降(P<0.05)。A组2 h CP水平明显高于B组(P<0.05)。结论胰岛素与西格列汀联用较单用胰岛素治疗成人隐匿性自身免疫糖尿病早期患者似乎能更好保护胰岛β细胞功能,西格列汀或可延长LADA非胰岛素依赖期的时间。

关键词: 成人隐匿性自身免疫性糖尿病, 西格列汀

Abstract: Objective The Objective of the study was to investigate the effects of the DPP-4 inhibitor on β-cell function in patients with recent-onset latent autoimmune diabetes in adults LADA. Methods Fourteen recently diagnosed LADA patients were randomized into two groups, A and B, to receive insulin therapy with 100 mg/d sitagliptin (group A, n=7) or without sitagliptin (group B, n=7) for 9 months. Results There were no differences in the clinical baseline data between the two groups. During the 9 months of follow-up, there were no significant differences in glucose and glycosylated hemoglobin levels between the two groups. At 9 months, there were not different in group A including fasting C-peptide (FCP), 2-hour postprandial C-peptide (CP), and ΔCP(ΔCP=2 h CP-FCP) levels (P>0.05). Compared with baseline, whereas in group B the levels of FCP, 2-hour CP and ΔCP were significantly decreased compared with baseline (P<0.05). Levels of 2-hour CP were higher in group A, it was higher than group B at 9 months (P<0.05). Conclusion LADA patients treated with sitagliptin and insulin was more likely maintain β-cell function by comparison with insulin alone. Sitagliptin administration in patients with LADA might prolong the insulin-free period.

Key words: Latent autoimmune diabetes in adults (LADA), Sitagliptin

赖菲菲, 李枢, 王吓勇. 胰岛素联合西格列汀治疗成人隐匿性自身免疫糖尿病早期患者的疗效观察[J]. 广州医药, 2017, 48(4): 46-50.

LAI Feifei, LI Shu, WANG Xiayong. Insulin with dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults[J]. Guangzhou Medical Journal, 2017, 48(4): 46-50.

参考文献

[1] ZHOU Z,XIANG Y,JI L,et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study[J]. Diabetes,2013,62(2):543-550.
[2] LAUGESEN E, ØSTERGAARD J A, LESLIE R D G. Latent autoimmune diabetes of the adult: current knowledge and uncertainty[J]. Diabet Med,2015,32(7):843-852.
[3] KIM J, NIAN C, MCINTOSH C H S. Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and-independent pathways[J]. Diabetes, 2010,59(7):1739-1750.
[4] MATTEUCCI E, GHIMENTI M, DI B S, et al. Altered proportions of naive, central memory and terminally differentiated central memory subsets among CD4+ and CD8+ T cells expressing CD26 in patients with type 1 diabetes[J]. J Clin Immunol, 2011,31(6):977-984.
[5] CASROUGE A,DECALF J,AHLOULAY M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV[J]. J Clin Invest,2011,121(12):308-317.
[6] DUVNJAK L, BLASLOV K,VučićL M, et al. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes[J]. Diabetes Res Clin Pract,2016(121):119-126.
[7] BROPHY S, BRUNT H, DAVIES H,et al. Interventions for latent autoimmune diabetes (LADA) in adults[J]. Cochrane Database Syst Rev,2011,7(3):92.
[8] 马燕,冯凯,李伟,等.起始应用胰岛素治疗对成人隐匿性自身免疫性糖尿病患者胰岛功能影响的回顾性分析,中国全科医师杂志[J]. 2016,15,(5):356-360.
[9] JOHASEN O E, BOEHM B O, GRILL V, et al. β-Cell function in latent autoimmune diabetes in adults treated with linagliptin vs glimepiride: exploratory results from a 2-year double-blind randomized controlled study[J]. Diabetologia,2012(55):S67-S68.
[10] JELSING J,VRANG N,van WITTELOOSTUIJN S B,et al. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice[J]. J Clin Endocrinol,2012,214(3):381-387.
[11] SHAH P, ARDESTANI A, DHARMADHIKARI G, et al. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization[J]. J Clin Endocrinol,2013,98(7):E1163-E1172.
[12] BUZZETTI R, POZZILLI P, FREDERICH R, et al. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA)[J]. Diabetes Metab Res Rev,2015,32(3):289-296.
[13] LIMA-Martínez M M, GUERRA-Alcalá E, CONTRERAS M, et al.One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin[J]. Endocrinol Diabetes Metab Case Rep,2014(2014):140072.
[14] NISHIOKA T, SHINOHARA M, TANIMOTO N, et al. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis[J]. Dermatololgy,2012,224(1):20-21.

胰岛素联合西格列汀治疗成人隐匿性自身免疫糖尿病早期患者的疗效观察

Insulin with dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价